Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181763 · ClinicalTrials.gov registry record · Phase 1
Evaluation of MDMA on Startle Response
A Phase 1 study, sponsored by Resilient Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03181763: Completed Phase 1 study, sponsored by Resilient Pharmaceuticals.
NCT03181763 is a Phase 1 study that has completed, run by Resilient Pharmaceuticals. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03181763, a Phase 1 study, has completed, sponsored by Resilient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants. The main question it aims to answer is: Does MDMA impact participant's performance on a startle test? Researchers will compare healthy volunteers who have taken MDMA to those who have taken placebo. Participants will first undergo a 1-hour startle test. The next day, they will be randomized to receive either MDMA or placebo followed by another startle test and vitals signs and blood measurements. Participants will return the next day for a final startle test. Their sleep will be tracked by a Fitbit device.
Primary Outcome
Description: Measure of startle response to noise after fear extinction training
Interventions
- DRUG Placebo
- DRUG Midomafetamine
- BEHAVIORAL Acoustic startle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-03-14 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 1 |
What the finished NCT03181763 record still lists
NCT03181763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03181763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03181763 about?
NCT03181763 is a clinical study titled "Evaluation of MDMA on Startle Response". The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants. The main question it aims to answer is: Does MDMA impact participant's performance on a startle test? Researchers will compare healthy volunteers who have taken MDMA to those who have taken placeb...
What is the current status of trial NCT03181763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-03-14. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT03181763?
The interventions under investigation include: Placebo (DRUG), Midomafetamine (DRUG), Acoustic startle (BEHAVIORAL).
Who is sponsoring clinical trial NCT03181763?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03181763's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI